-

Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray in Help in Combating SARS-CoV-2

WASHINGTON--(BUSINESS WIRE)--Xlear has filed a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA) seeking approval to make claims that the nasal spray is approved for use in preventing SARS-CoV-2 (COVID-19) transmission and infection. The Pre-EUA is a first step in seeking formal authorization of Xlear Nasal Spray as tool to help in combatting COVID-19.

Xlear previously filed a pre-EUA seeking approval for use of the nasal spray as a medical device in combatting COVID-19. However, because the FDA determined that Xlear “works against the virus,” the FDA told Xlear it would need to be considered as a drug or combination product EUA.

“Seeing that the FDA says Xlear works against the virus, we have decided to seek EUA approval as a drug,” said Nathan Jones, Xlear’s CEO.

Xlear’s Pre-EUA Request is based on recent studies showing the nasal spray is:

  • virucidal (it kills the virus);
  • antiviral (it blocks the adhesion of the virus to the nasal membrane, which is how most people get sick from COVID-19);
  • antibacterial against streptococcus bacteria, which is the leading cause of bacterial pneumonia (a COVID-19 complication linked to morbidity); and,
  • Reduces both the duration and severity of illness when used to treat COVID-19 patients.

Xlear is currently sold in over 50,000 pharmacies, grocery stores, and online as a nasal spray. “Xlear doesn’t require the EUA to be sold and used—we only need an EUA to be able to inform people about the benefits of using Xlear to protect themselves from COVID-19. It’s insane. Without the EUA, the Federal Trade Commission won’t let us simply inform people about new, published, independent scientific studies,” Jones added.

“We hope to move forward quickly with FDA to address gaps in current prevention and treatment strategies against SARS-CoV-2. People should be using Xlear as part of a layered defense to prevent getting COVID-19. If everyone used Xlear, in addition to taking other steps recommended by public health officials, we believe we could help the nation defeat COVID-19 faster,” Jones added.

More information on Xlear: https://xlear.com/

Contacts

Jeff Gulko
617.304.7339
jeff@thegulkogroup.com

Xlear


Release Summary
Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray in Help in Combating SARS-CoV-2

Contacts

Jeff Gulko
617.304.7339
jeff@thegulkogroup.com

Social Media Profiles
More News From Xlear

Xlear Sues FTC for Unlawful Scientific Censorship

SALT LAKE CITY--(BUSINESS WIRE)--Xlear Sues FTC for Unlawful Scientific Censorship; FTC’s marketing substantiation rules violate Supreme Court Loper Ruling...

Xlear, Inc. Commends Utah for its Leadership Role in Being the First State in the Nation to Ban Fluoride from its Public Drinking Water

AMERICAN FORK, Utah--(BUSINESS WIRE)--Nathan Jones, CEO of Xlear, Inc. a Utah-based leading natural health products company, issues the following statement. “As CEO of Xlear, Inc., and a keen proponent of eliminating fluoride from public drinking water, I congratulate Utah’s historic decision to become the first state to ban the addition of fluoride to its public and residential water systems. "The passing of HB0081 by the Utah legislature represents a pivotal moment for health freedom and indi...

DOJ Asks Court to Dismiss FTC-Xlear Lawsuit

AMERICAN FORK, Utah--(BUSINESS WIRE)--DOJ ASKS COURT TO DISMISS FTC-XLEAR LAWSUIT; Calls into Question FTC’s Authority to Require Clinical Studies for Non-Pharmaceutical Health Products...
Back to Newsroom